Advances in surgical techniques and the growing elderly population have led to an increasing number of medical devices—such as catheters and stents—being implanted inside the human body. Over time, however, these implanted devices accumulate various biological contaminants, including proteins, cells, and bacteria. This buildup can trigger complications such as infections, inflammation, thrombosis, and calcification. These issues cause patient discomfort, degrade device performance, and often result in repeated procedures, ultimately imposing a significant healthcare burden.
In addition, endoscopes used during surgery frequently fog up due to the high humidity inside the human body, and blood often adheres to their surface. As a result, surgeons must repeatedly withdraw the endoscope for cleaning before resuming the procedure. In fact, approximately 20% of total surgery time is reportedly spent on endoscope cleaning, and some operating rooms even assign dedicated staff for this task.
To solve these problems, a startup named Lynk Solutec has developed an innovative coating technology. The company has created a nano–lubricant-film–based anti-biofouling coating called LYNK Coating, inspired by the surface structure of the butterwort plant. This technology suppresses biological adhesion purely through physical and chemical control—without using drugs—and can be uniformly applied to diverse materials such as polymers, metals, and ceramics, as well as to complex device geometries. On the company’s website, detailed demonstration videos show the performance of Clean View, a non-fogging, blood-repellent endoscope coating, along with the LYNK Solution anti-biofouling coatings and release agents designed to prevent surface contamination.
Lynk Solutec’s endoscopic products have already received Class I regulatory approval and are undergoing clinical validation at major hospitals. The company also plans to launch coated catheters, ureteral stents, and other product lines once regulatory processes are complete.
Lynk Solutec was founded in 2020 by Professor Jungmook Seo, who earned his PhD in electrical and electronic engineering from Yonsei University and later served as a postdoctoral fellow at Harvard Medical School, and Dr. Yeontaek Lee, who studied materials science and electrical engineering at Yonsei University. One of the company’s strengths is its fully integrated development system—from research and product development to regulatory approval and mass manufacturing.
The company raised a ₩1 billion seed investment from Daily Partners and the Yonsei University Technology Holdings in 2022, followed by selection for the TIPS program. In 2025, it secured ₩1.5 billion in Pre-A funding from POSTECH Holdings and the Korea Technology Finance Corporation, demonstrating strong validation of its technology. Lynk Solutec will present its vision for global expansion at the PR Day event hosted by POSTECH Holdings on December 5.
What problem is Lynk Solutec solving, and how?
Implanted medical devices develop surface contamination over time—proteins, bacteria, and other bio-substances—that lead to infections, inflammation, thrombosis, and calcification. These complications degrade device performance and often require additional surgical procedures.
To address these issues fundamentally, we developed LYNK Coating, a nano–lubricant-film–based anti-biofouling technology.
Inspired by the surface structure of the butterwort plant, the coating forms an ultrathin lubricating layer that prevents adherence from millimeter-scale contaminants down to microscopic proteins. Since it suppresses adhesion without using drugs, it offers high safety and long-term stability. It can be uniformly applied to polymers, metals, ceramics, and even devices with complex geometries. Ultimately, it can extend device lifespan, reduce complications, and lower healthcare costs.
What are the technical advantages of your products and services?
Our core technology is LYNK Coating, applied across a wide range of implanted medical devices—from the Clean View endoscopic coating to silicone catheters and ureteral stents.
The technology fundamentally blocks biological adhesion without drugs, ensuring both durability and safety. It enables uniform coating across diverse materials and complex structures, and can be applied easily within GMP manufacturing environments.
Our endoscopic products have already obtained Class I approval and are undergoing real-world clinical testing in major hospitals. Our implantable product lines—including ureteral stents, catheters, and ptosis-correction sutures—are now progressing through regulatory stages.
What is the target market size, key customers, and the business model?
The global medical device market reached roughly KRW 726 trillion in 2023, with the implantable device segment alone accounting for about KRW 168 trillion. We are initially targeting medium- to long-term implantable devices that frequently contact blood or bodily fluids and plan to address a market of approximately KRW 55 trillion by 2030.
Our key customers include medical device manufacturers, tertiary hospitals, and public procurement agencies.
Our business model has two phases:
- Phase 1: Direct sales of coated medical devices to validate the technology and generate initial revenue.
- Phase 2: Expansion into coating-technology licensing, coating-solution and equipment supply, and OEM manufacturing.
Through clinical validation and procurement-based pilot programs, we aim to enter the market and scale globally with our technological, quality, and GMP-based manufacturing capabilities.
What achievements has Lynk Solutec made so far?
Lynk Solutec secured a ₩1 billion seed investment from Daily Partners and Yonsei University Technology Holdings in 2022, followed by TIPS selection (₩500 million). In 2025, the company raised ₩1.5 billion in Pre-A funding from POSTECH Holdings and the Korea Technology Finance Corporation.
With these investments, we accelerated R&D and successfully built a portfolio of five domestic patents, two foreign patent applications, five coating pipelines, and four product lines.
What is the team structure, and what makes it competitive?
Lynk Solutec is a technology-driven medical device startup founded by Professor Jungmook Seo—PhD in electrical and electronic engineering and former postdoctoral fellow at Harvard Medical School—and Dr. Yeontaek Lee, who specialized in materials science and electrical engineering at Yonsei University.
We operate an in-house system that connects research, product development, regulatory approval, and mass manufacturing. This allows us to translate ideas into actual medical devices quickly. Ongoing collaborations with major hospitals—including Boramae Hospital, Korea University Ansan Hospital, and Severance Hospital—provide continuous clinical validation and field insights.
This integrated team structure of research, clinical testing, and manufacturing enables us to rapidly mitigate risks in clinical approval and mass production.
How has POSTECH Holdings supported Lynk Solutec?
POSTECH Technology Holdings has gone beyond investment by facilitating partnerships with hospitals and offering ongoing support. Through their consulting for follow-on fundraising, we strengthened our IR capabilities and refined our business direction.
What message would you like to deliver to investors at the upcoming PR Day Demo Day?
This Demo Day comes at a pivotal moment—as we prepare for FDA and CE regulatory submissions and global commercialization.
Our coating technology solves infection, thrombosis, and calcification challenges in implantable devices without drugs. Our flagship product, Clean View, has already secured regulatory approval and adoption in hospital pilot programs, generating real revenue. Our founding team includes two PhD-level experts, supported by GMP-based manufacturing infrastructure and a strong network of clinical advisors, enabling us to minimize risks in clinical, regulatory, and production stages.
With our technology validated and market traction confirmed, now is the ideal time for investors to join us as we transition into the second stage of our business model and accelerate global growth.
